Fujian Cosunter Pharmaceutical Co Ltd (SHE:300436) — Market Cap & Net Worth
Market Cap & Net Worth: Fujian Cosunter Pharmaceutical Co Ltd (300436)
Fujian Cosunter Pharmaceutical Co Ltd (SHE:300436) has a market capitalization of $2.73 Billion (CN¥18.68 Billion) as of May 2, 2026. Listed on the SHE stock exchange, this China-based company holds position #5220 globally and #1029 in its home market, demonstrating a 0.17% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Fujian Cosunter Pharmaceutical Co Ltd's stock price CN¥117.30 by its total outstanding shares 159267000 (159.27 Million). Analyse 300436 operating cash flow to see how efficiently the company converts income to cash.
Fujian Cosunter Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Fujian Cosunter Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.92 Billion to $2.73 Billion (5.05% CAGR).
Fujian Cosunter Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Fujian Cosunter Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.72x
Fujian Cosunter Pharmaceutical Co Ltd's market cap is 1.72 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.92 Billion | $308.92 Million | $103.49 Million | 6.21x | 18.54x |
| 2016 | $1.25 Billion | $312.88 Million | $66.41 Million | 3.99x | 18.80x |
| 2017 | $682.54 Million | $296.12 Million | $33.57 Million | 2.30x | 20.33x |
| 2018 | $565.16 Million | $402.40 Million | $16.48 Million | 1.40x | 34.28x |
| 2019 | $776.32 Million | $414.87 Million | $10.74 Million | 1.87x | 72.27x |
| 2020 | $900.53 Million | $368.49 Million | $14.82 Million | 2.44x | 60.75x |
| 2021 | $1.12 Billion | $370.44 Million | -$34.89 Million | 3.02x | N/A |
| 2022 | $912.65 Million | $385.77 Million | -$127.40 Million | 2.37x | N/A |
| 2023 | $597.33 Million | $422.71 Million | -$348.59 Million | 1.41x | N/A |
| 2024 | $761.40 Million | $441.46 Million | -$156.30 Million | 1.72x | N/A |
Competitor Companies of 300436 by Market Capitalization
Companies near Fujian Cosunter Pharmaceutical Co Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Fujian Cosunter Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Fujian Cosunter Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Fujian Cosunter Pharmaceutical Co Ltd's market cap moved from $1.92 Billion to $ 2.73 Billion, with a yearly change of 5.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.73 Billion | +31.58% |
| 2025 | CN¥2.08 Billion | +172.88% |
| 2024 | CN¥761.40 Million | +27.47% |
| 2023 | CN¥597.33 Million | -34.55% |
| 2022 | CN¥912.65 Million | -18.47% |
| 2021 | CN¥1.12 Billion | +24.30% |
| 2020 | CN¥900.53 Million | +16.00% |
| 2019 | CN¥776.32 Million | +37.36% |
| 2018 | CN¥565.16 Million | -17.20% |
| 2017 | CN¥682.54 Million | -45.32% |
| 2016 | CN¥1.25 Billion | -34.94% |
| 2015 | CN¥1.92 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Fujian Cosunter Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.73 Billion USD |
| MoneyControl | $2.73 Billion USD |
| MarketWatch | $2.73 Billion USD |
| marketcap.company | $2.73 Billion USD |
| Reuters | $2.73 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Fujian Cosunter Pharmaceutical Co Ltd
Fujian Cosunter Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It offers drugs for anti-HBV, liver diseases, hepatobiliary disease drugs, metabolism and digestive system, respiratory, cardiovascular, men's health, and other fields. Fujian Cosunter Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Fuzh… Read more